Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation-Reference-Cited by-同舟云学术

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation

Published:2021-02-07 Issue:6 Volume:238 Page:1495-1511
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Nirogi Ramakrishna,Benade Vijay,Daripelli Saivishal,Subramanian Ramkumar,Kamuju Venkatesh,Bhyrapuneni Gopinadh,Muddana Nageswara Rao,Mekala Venkat Reddy,Petlu Surendra,Jayarajan Pradeep,Badange Rajesh,Shinde Anil,Jasti Venkat

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s00213-021-05779-x.pdf

Reference56 articles.

1. Arrang JM, Garbarg M, Schwartz JC (1987) Auto-inhibition of histamine synthesis mediated by presynaptic H3 receptors. Neuroscience 23:149–157

2. Baker JG (2008) Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. BMC Pharmacol 8:9

3. Barnes J, Brown J, Clarke N, Clapham J, Evans D, O’Shaughnessy C (1993) Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. Eur J Pharmacol 250:147–152

4. Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y (2019) Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 15:519–539

5. Black SW, Yamanaka A, Kilduff TS (2017) Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 152:89–113

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From past to future: 50 years of pharmacological interventions to treat narcolepsy;Pharmacology Biochemistry and Behavior;2024-08

2. Hits and misses with animal models of narcolepsy and the implications for drug discovery;Expert Opinion on Drug Discovery;2024-05-15

3. Discovery of Novel Steroid-Based Histamine H₃ Receptor Antagonists/Inverse Agonists;Journal of Medicinal Chemistry;2024-02-23

4. Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep–Wake Cycle Disorder;Frontiers in Pharmacology;2022-06-01

5. The development of sleep/wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice;Sleep;2022-02-19